Press Releases

Press Releases

Octagos Health announces strategic investments in product, AI and talent

Following its recent $43 million Series B funding, the company is expanding its data integration capabilities to include a broader range of devices, including wearables, heart failure monitoring, and remote patient monitoring.

Elutia announces first patient implant of EluPro, the world’s first drug-eluting bioenvelope for cardiac pacemakers and neurostimulators

The procedure was performed in Greenville, North Carolina.

2023 Hearst Health Prize - AI for Incidental CAC

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

DASI Simulations' PrecisionTAVI gets CMS Hospital Outpatient Billing Code

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

 

Echo IQ's breakthrough research on cardiovascular health continues with unveiling of AI-driven aortic stenosis and mitral regurgitation detection results at ESC 2023 Congress

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

 

Keystone Perfusion Services, PC recognized for life-saving contribution during COVID-19 pandemic, secures fifth consecutive year on Inc. 5000 list
| Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

 

Corazon and the Society for Cardiovascular Angiography and Interventions announce partnership

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta announces SpotLight Duo, the world’s first dedicated cardiovascular and thoracic CT system

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

 

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately. 

 

Cassling connects cardiologists with revolutionary AI software

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

 

DASI Simulation’s Precision TAVI earns FDA clearance
| Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

 

 

RecoverRite®, American College of Cardiology Collaborate to Change the Face of Cardiovascular Patient Education

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

Study shows PulseAI’s deep learning algorithm outperforms the Apple Watch ECG algorithm in detecting atrial fibrillation

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

 

$20M gift announced by the Rooney Foundation in support of enhanced cardiac care at NCH

NAPLES, Fla. – February 20, 2023   The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney.  In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NCH announces second historic gift in as many weeks totaling a record $40M in support of enhanced care

NAPLES, Fla. – February 21, 2023   On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard.  This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida.  Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

Patient Image Exchange puts patients 'in the driver’s seat'

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

 

Ancora Heart appoints David J. Tucker as chief financial officer

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure presents data successfully identifying responders and non-responders to renal denervation using genetic screening

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

97% One-Year Survival for Patients at High Risk of Sudden Cardiac Death Prescribed the Zoll Lifevest Wearable Defibrillator

June 10, 2016—CHELMSFORD, MASS.—ZOLL®Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced that patients experience a high one-year survival rate following use of the LifeVest® Wearable Defibrillator. New results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry) were presented today by Valentina Kutyifa, MD, PhD, University of Rochester Medical Center, during the Late-Breaking Clinical Trials session at CARDIOSTIM/EUROPACE 2016.

Cardiostim 2016: Growing Importance of Remote Monitoring and Potential for New Heart Monitor Indications Detailed at Scientific Session

(PresseBox) BIOTRONIK Home Monitoring® received strong endorsements during the Cardiostim scientific session “Improving Patient Outcomes in Arrhythmia Management.” 

New Data Further Demonstrate Safety Benefits for World's Smallest Pacemaker

DUBLIN and NICE, FRANCE - JUNE 9, 2016 - Medtronic plc (NYSE:MDT) today announced new results from the Medtronic Micra® Transcatheter Pacing System (TPS) Global Clinical Trial in a late-breaking trial session at CARDIOSTIM / EHRA EUROPACE 2016, the World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. 

Medtronic Announces Results of Early Feasibility Studies Supporting New Approach to ICD Therapy During Cardiostim 2016

DUBLIN and NICE, FRANCE - JUNE 8, 2016 - Medtronic plc (NSYE: MDT) today announced results from several feasibility studies evaluating a new approach to implantable cardioverter defibrillator (ICD) therapy at CARDIOSTIM / EHRA EUROPACE 2016, the World Congress in Electrophysiology and Cardiac Techniques, in Nice, France.

Lombard Medical Provides Update on Controlled Launch of the New Altura® Endovascular Stent Graft in Europe

IRVINE, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the following commercial update of the new Altura® Endovascular Stent Graft System.

World Congestive Heart Failure (CHF) Treatment Devices Market Is Expected to Reach $14.8 Billion by 2022 - Allied Market Research

A new report published by Allied Market Research titled, World Congestive Heart Failure (CHF) Treatment Devices Market - Opportunities and Forecasts, 2015 -2022, projects that the world CHF treatment devices market would reach $14.8 billion by 2022, at a CAGR of 5.5% from 2016 to 2022. Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate the world CHF treatment devices market throughout the forecast period. North America is projected to continue its lead in terms of revenue, accounting for more than two-fifths share of the world CHF treatment devices.

Final Subject Enrolled in Early Feasibility Study of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) today announced completion of enrollment into its early feasibility study evaluating the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE) for the treatment of aortic aneurysms involving the visceral branch vessels. The TAMBE is designed to be the first complete off-the-shelf solution for the treatment of this complex disease. The device adds to Gore’s comprehensive portfolio of aortic branch solutions designed to effectively treat aortic aneurysms through minimally invasive means.

Late-Breaking Clinical Trial: WEARIT-II One-Year Follow-Up Results of Wearable Defibrillator Use to be Presented at Cardiostim/Europace 2016

June 2, 2016—CHELMSFORD, MASS.—ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Valentina Kutyifa, MD, PhD, University of Rochester Medical Center will present, “One-Year Follow-Up of the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry)” during the Late-Breaking Clinical Trials session at CARDIOSTIM/EUROPACE 2016 in Nice, France on Friday, 10 June, 09:00, Room 1.4–Level 1/Méditerranée, Session #168-01.

Practicing Cardiologists Recognized as "Health Care Heroes" After Developing Their Own Cardiovascular Software

(NEW ORLEANS) — Dr. Vinod Nair, President and Chief Software Architect of Objective Medical Systems (OMS), and Dr. Peter Fail, Chief Privacy Officer, have been selected as New Orleans CityBusiness Health Care Heroes for 2016, placing them among the top medical professionals in the Greater New Orleans area.

Edwards' Surgical Heart Valve Innovations Demonstrate Positive Patient Benefits

BALTIMORE, May 17, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced positive clinical trial results on two of its advanced innovations in surgical heart valves for the treatment of people with aortic valve disease. Data from three studies—COMMENCE, TRANSFORM and FOUNDATION—were presented as part of the late-breaking sessions at the American Association for Thoracic Surgery's (AATS) 96th annual meeting.  

First-ever pediatric feasibility study results set stage for clinical trial of world’s first bioabsorbable heart valve-enabling Endogenous Tissue Restoration

12-month follow-up data on bioabsorbable technology presented today at annual meeting of American Association for Thoracic Surgery.

Endologix Completes Patient Enrollment in the Ovation® LIFE (Least Invasive Fast-Track EVAR) Study

IRVINE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has completed patient enrollment in the LIFE study, a multi-center post-market registry designed to evaluate the Ovation ® Abdominal Stent Graft Platform when used in the treatment of patients with abdominal aortic aneurysms ("AAA") using a Fast-Track EVAR protocol. 

Medicure Files Application for New AGGRASTAT® Product Format

WINNIPEG, May 11, 2016 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that it has submitted an application to the U.S. Food and Drug Administration (FDA) for the introduction of a new "bolus vial" product format for AGGRASTAT (tirofiban HCl).  

St. Jude Medical Announces MultiPoint Pacing IDE Study Results During Late-Breaker at Heart Rhythm 2016

This study builds on the growing body of evidence for managing heart failure using the St. Jude Medical MultiPoint pacing technology for patients not responsive to other therapy options

New Data Further Support Medtronic Leadership in Leadless Pacing at Heart Rhythm 2016

DUBLIN and SAN FRANCISCO - May 5, 2016 - Medtronic plc (NYSE:MDT) today announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra® Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions in San Francisco.

Medtronic Receives FDA Approval for New Single-Chamber ICDs That Detect Atrial Fibrillation

DUBLIN - May 2, 2016 - Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the Visia AF MRI(TM) SureScan® and Visia AF(TM) single-chamber implantable cardioverter defibrillators (ICDs). The Visia AF devices can detect previously undiagnosed and/or asymptomatic atrial fibrillation (AF) and monitor recurrent AF, while treating life-threatening rhythms in the lower chambers of the heart. The Visia AF ICD systems will be commercially available in early summer.

Boston Scientific Announces CE Mark For MRI Labeling Of Emblem™ S-ICD Systems

MARLBOROUGH, Mass., April 20, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted EMBLEM S-ICD Systems. 

Verseon presents further trial data on the low bleeding risk of its family of preclinical anti-coagulant drugs at BioEurope conference

Fremont, California – Further evidence on the low bleeding profile of Verseon’s novel family of anti-coagulants was presented at the BioEurope conference in Stockholm, Sweden last week. The new data reinforces the promise of Verseon’s novel, highly selective direct thrombin inhibitors (DTIs) as a potential treatment for venous thrombotic disorders while maintaining a lower bleeding risk than current drugs.

Lund University Hospital Study Validates Improved Long-Term Clinical Outcomes Using Stereotaxis Technology

ST. LOUIS, April 07, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a long-term follow-up study on the efficacy of the Stereotaxis Niobe® ES magnetic navigation system reported by Lund University Hospital in Sweden, which validate improved long-term clinical outcomes compared to manual navigation for ablation treatment of atrial fibrillation (AF).

Hartford HealthCare Announces Heart and Vascular Institute Appointments

HARTFORD, Conn. , April 6, 2016 /PRNewswire/ -- Hartford HealthCare has appointed Dr. Sabet W. Hashim as chairman of cardiac surgery and co-physician-in-chief of the Hartford HealthCare Heart and Vascular Institute. Dr. Hashim, an international leader in cardiac surgery, will work collaboratively with internationally recognized Hartford Hospital cardiologist Dr. Paul Thompson, who also has been named the Institute's Co-Physician-in-Chief.

Medtronic CoreValve® System Maintains Survival Advantages Over Surgery in High Risk Aortic Stenosis Patients at Three Years

DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) today announced new data from the High Risk Study of the CoreValve U.S. Pivotal Trial that show superior clinical outcomes for transcatheter aortic valve replacement (TAVR) with the CoreValve® System compared to surgical aortic valve replacement (SAVR) out to three years. The positive data were published in the Journal of American College of Cardiology and simultaneously presented during a Featured Clinical Research session at 65th Annual Scientific Session & Expo of the American College of Cardiology (ACC.16).